id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-D-0030-0012,FDA,FDA-2003-D-0030,FDA,Notice,N-Notice,2006-12-20T05:00:00Z,2006,12,,,2008-04-12T00:54:03Z,,0,0,090000648048154e
FDA-2003-D-0030-0011,FDA,FDA-2003-D-0030,FDA,Notice,NM-Notice of Meeting,2006-11-02T05:00:00Z,2006,11,2006-10-31T05:00:00Z,,2008-04-12T00:54:01Z,,0,0,0900006480481546
FDA-2003-D-0030-0009,FDA,FDA-2003-D-0030,GUIDANCE,Supporting & Related Material,GDL-Guidance,2006-06-16T04:00:00Z,2006,6,,,2008-04-12T00:54:04Z,,0,0,0900006480481531
FDA-2003-D-0030-0010,FDA,FDA-2003-D-0030,FDA,Notice,NAD-Notice of Availability of Data,2006-06-16T04:00:00Z,2006,6,2006-06-08T04:00:00Z,,2008-04-12T00:54:03Z,,0,0,0900006480481532
FDA-2003-D-0030-0008,FDA,FDA-2003-D-0030,GUIDANCE,Supporting & Related Material,GDL-Guidance,2006-06-16T04:00:00Z,2006,6,,,2008-04-12T00:54:01Z,,0,0,0900006480481530
FDA-2003-D-0030-0007,FDA,FDA-2003-D-0030,Congressional Report: Feasibility and Cost of a New Monograph System for Marketed Unapproved Drugs,Other,RPT-Report (outside of agency unless indicated),2006-06-07T04:00:00Z,2006,6,,,2008-04-12T00:54:02Z,,0,0,090000648048152e